tant administration of other drugs that inhibit the activity of p450 2d6 may acutely increase plasma concentrations of antipsychotics. among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine. when prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity. lower doses than usually prescribed for either the antipsychotic or the other drug may be required.

rreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. however, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. there is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, and thereby may possibly mask the underlying disease process. the effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. given these considerations, especially in the elderly, antipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that 1) is known to respond to antipsychotic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. in patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. the need for continued treatment should be reassessed periodically. if signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. however, some patients may require treatment despite the presence of the syndrome. (for further information about the description of tardive dyskinesia and its clinical detection, please refer to information for patients and adverse reactions .) neuroleptic malignant syndrome (nms) a potentially fatal symptom complex, sometimes referred to as neuroleptic malignant syndrome (nms), has been reported in association with antipsychotic drugs. clinical manifestations of nms are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). the diagnostic evaluation of patients with this syndrome is complicated. in arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (eps). other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (cns) pathology. the management of nms should include 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. there is no general agreement about specific pharmacological treatment regimens for uncomplicated nms. if a patient requires antipsychotic drug treatment after recovery from nms, the reintroduction of drug therapy should be carefully considered. the patient should be carefully monitored, since recurrences of nms have been reported. if hypotension develops, epinephrine should not be administered since its action is blocked and partially reversed by perphenazine. if a vasopressor is needed, norepinephrine may be used. severe, acute hypotension has occurred with the use of phenothiazines and is particularly likely to occur in patients with mitral insufficiency or pheochromocytoma. rebound hypertension may occur in pheochromocytoma patients. perphenazine products can lower the convulsive threshold in susceptible individuals; they should be used with caution in alcohol withdrawal and in patients with convulsive disorders. if the patient is being treated with an anticonvulsant agent, increased dosage of that agent may be required when perphenazine products are used concomitantly. perphenazine products should be used with caution in patients with psychic depression. perphenazine may impair the mental and/or physical abilities required for the performance of hazardous tasks such as driving a car or operating machinery; therefore, the patient should be warned accordingly. perphenazine products are not recommended for pediatric patients under 12 years of age. usage in pregnancy non-teratogenic effects neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. there have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. these complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization. perphenazine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. safe use of perphenazine during pregnancy and lactation has not been established; therefore, in administering the drug to pregnant patients, nursing mothers, or women who may become pregnant, the possible benefits must be weighed against the possible hazards to mother and child.

imes a day initially; reduce as soon as possible to minimum effective dosage. hospitalized patients with schizophrenia 8 to 16 mg two times a day to four times a day; avoid dosages in excess of 64 mg daily. severe nausea and vomiting in adults 8 to 16 mg daily in divided doses; 24 mg occasionally may be necessary; early dosage reduction is desirable. elderly patients with increasing age, plasma concentrations of perphenazine per daily ingested dose increase. geriatric dosages of perphenazine preparations have not been established, but initiation of lower dosages is recommended. optimal clinical effect or benefit may require lower doses for a longer duration. dosing of perphenazine may occur before bedtime, if required.

ymptoms can usually be controlled by the concomitant use of effective antiparkinsonian drugs, such as benztropine mesylate, and/or by reduction in dosage. in some instances, however, these extrapyramidal reactions may persist after discontinuation of treatment with perphenazine. dystonia class effect: symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. while these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. an elevated risk of acute dystonia is observed in males and younger age groups. persistent tardive dyskinesia as with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy or may appear after drug therapy has been discontinued. although the risk appears to be greater in elderly patients on high-dose therapy, especially females, it may occur in either sex and in children. the symptoms are persistent and in some patients appear to be irreversible. the syndrome is characterized by rhythmical, involuntary movements of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). sometimes these may be accompanied by involuntary movements of the extremities. there is no known effective treatment for tardive dyskinesia; antiparkinsonism agents usually do not alleviate the symptoms of this syndrome. it is suggested that all antipsychotic agents be discontinued if these symptoms appear. should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked. it has been reported that fine, vermicular movements of the tongue may be an early sign of the syndrome, and if the medication is stopped at that time the syndrome may not develop. other cns effects include cerebral edema; abnormality of cerebrospinal fluid proteins; convulsive seizures, particularly in patients with eeg abnormalities or a history of such disorders; and headaches. neuroleptic malignant syndrome has been reported in patients treated with antipsychotic drugs (see warnings ). drowsiness may occur, particularly during the first or second week, after which it generally disappears. if troublesome, lower the dosage. hypnotic effects appear to be minimal, especially in patients who are permitted to remain active. adverse behavioral effects include paradoxical exacerbation of psychotic symptoms, catatonic-like states, paranoid reactions, lethargy, paradoxical excitement, restlessness, hyperactivity, nocturnal confusion, bizarre dreams, and insomnia. hyperreflexia has been reported in the newborn when a phenothiazine was used during pregnancy. autonomic effects dry mouth or salivation, nausea, vomiting, diarrhea, anorexia, constipation, obstipation, fecal impaction, urinary retention, frequency or incontinence, bladder paralysis, polyuria, nasal congestion, pallor, myosis, mydriasis, blurred vision, glaucoma, perspiration, hypertension, hypotension, and change in pulse rate occasionally may occur. significant autonomic effects have been infrequent in patients receiving less than 24 mg perphenazine daily. adynamic ileus occasionally occurs with phenothiazine therapy, and if severe, can result in complications and death. it is of particular concern in psychiatric patients, who may fail to seek treatment of the condition. allergic effects urticaria, erythema, eczema, exfoliative dermatitis, pruritus, photosensitivity, asthma, fever, anaphylactoid reactions, laryngeal edema, and angioneurotic edema; contact dermatitis in nursing personnel administering the drug; and in extremely rare instances, individual idiosyncrasy or hypersensitivity to phenothiazines has resulted in cerebral edema, circulatory collapse, and death. endocrine effects lactation, galactorrhea, moderate breast enlargement in females and gynecomastia in males on large doses, disturbances in the menstrual cycle, amenorrhea, changes in libido, inhibition of ejaculation, syndrome of inappropriate adh (antidiuretic hormone) secretion, false positive pregnancy tests, hyperglycemia, hypoglycemia, glycosuria. cardiovascular effects postural hypotension, tachycardia (especially with sudden marked increase in dosage), bradycardia, cardiac arrest, faintness, and dizziness. occasionally the hypotensive effect may produce a shock-like condition. ecg changes, nonspecific (quinidine-like effect) usually reversible, have been observed in some patients receiving phenothiazine antipsychotics. sudden death has occasionally been reported in patients who have received phenothiazines. in some cases, the death was apparently due to cardiac arrest; in others, the cause appeared to be asphyxia due to failure of the cough reflex. in some patients, the cause could not be determined nor could it be established that the death was due to the phenothiazine. hematological effects agranulocytosis, eosinophilia, leukopenia, hemolytic anemia, thrombocytopenic purpura, and pancytopenia. most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy. patients should be watched closely, especially during that period, for the sudden appearance of sore throat or signs of infection. if white blood cell and differential cell counts show significant cellular depression, discontinue the drug and start appropriate therapy. however, a slightly lowered white count is not in itself an indication to discontinue the drug. other effects special considerations in long-term therapy include pigmentation of the skin, occurring chiefly in the exposed areas; ocular changes consisting of deposition of fine particulate matter in the cornea and lens, progressing in more severe cases to star-shaped lenticular opacities; epithelial keratopathies; and pigmentary retinopathy. also noted: peripheral edema, reversed epinephrine effect, increase in pbi not attributable to an increase in thyroxine, parotid swelling (rare), hyperpyrexia, systemic lupus erythematosus-like syndrome, increases in appetite and weight, polyphagia, photophobia, and muscle weakness. liver damage (biliary stasis) may occur. jaundice may occur, usually between the second and fourth weeks of treatment, and is regarded as a hypersensitivity reaction. incidence is low. the clinical picture resembles infectious hepatitis but with laboratory features of obstructive jaundice. it is usually reversible; however, chronic jaundice has been reported. to report suspected adverse reactions, contact actavis at 1-800-272-5525 or fda at 1-800-fda-1088 or www.fda.gov/medwatch .

tant administration of other drugs that inhibit the activity of p450 2d6 may acutely increase plasma concentrations of antipsychotics. among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine. when prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity. lower doses than usually prescribed for either the antipsychotic or the other drug may be required.

with the hydroxylation of debrisoquine which is mediated by cytochrome p450 2d6 (cyp 2d6) and thus is subject to genetic polymorphism – i.e., 7% to 10% of caucasians and a low percentage of asians have little or no activity and are called “poor metabolizers.” poor metabolizers of cyp 2d6 will metabolize perphenazine more slowly and will experience higher concentrations compared with normal or “extensive” metabolizers.

n of debrisoquine which is mediated by cytochrome p450 2d6 (cyp 2d6) and thus is subject to genetic polymorphism – i.e., 7% to 10% of caucasians and a low percentage of asians have little or no activity and are called “poor metabolizers.” poor metabolizers of cyp 2d6 will metabolize perphenazine more slowly and will experience higher concentrations compared with normal or “extensive” metabolizers.